SSA
RVMD icon

Schonfeld Strategic Advisors’s Revolution Medicines RVMD Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-34,575
Closed -$1.61M – 2522
2025
Q3 		$1.61M Buy
34,575
+21,552
+165% +$844K 0.01% 1148
2025
Q2 		$479K Sell
13,023
-6,647
-34% -$255K ﹤0.01% 1551
2025
Q1 		$696K Sell
19,670
-330
-2% -$13.4K ﹤0.01% 1441
2024
Q4 		$875K Buy
20,000
+12,579
+170% +$635K 0.01% 1176
2024
Q3 		$337K Buy
+7,421
New +$323K ﹤0.01% 1606

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Schonfeld Strategic Advisors's RVMD Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Revolution Medicines (RVMD) in Q4 2025, closing a stake of 34,575 shares — an estimated $1.61M sold.

Schonfeld Strategic Advisors first reported a position in RVMD in Q3 2024 and held it in 5 quarters. The position peaked at $1.61M in Q3 2025. 386 funds tracked by Wall St. Rank hold RVMD as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Revolution Medicines position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 34,575 Revolution Medicines shares in Q4 2025, an estimated $1.61M.
  • Schonfeld Strategic Advisors first reported a position in Revolution Medicines in Q3 2024 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Revolution Medicines position peaked at $1.61M in Q3 2025.
  • 386 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.